About Glypican-5
Glypican-5 (GPC5) is a protein
from Homo sapiens identified by UniProt accession
P78333, 572 residues long.
MolForge cross-references it against 0 known binders and
247 disease associations.
Target properties
| Protein name | Glypican-5 |
| UniProt accession | P78333 |
| Gene | GPC5 |
| Organism | Homo sapiens |
| Length | 572 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (247)
Diseases linked to this target (Open Targets).
- COVID-19 · score 0.54
- body height · score 0.47
- blood protein measurement · score 0.44
- self reported educational attainment · score 0.44
- forced expiratory volume · score 0.43
- mathematical ability · score 0.42
- FEV/FVC ratio · score 0.42
- monocyte count · score 0.41
- intelligence · score 0.41
- appendicular lean mass · score 0.41
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P78333-F1 | alphafold | PREDICTED | 77.92 | — |
Amino-acid sequence (572 residues)
MDAQTWPVGF RCLLLLALVG SARSEGVQTC EEVRKLFQWR LLGAVRGLPD SPRAGPDLQV CISKKPTCCT RKMEERYQIA ARQDMQQFLQ TSSSTLKFLI SRNAAAFQET LETLIKQAEN YTSILFCSTY RNMALEAAAS VQEFFTDVGL YLFGADVNPE EFVNRFFDSL FPLVYNHLIN PGVTDSSLEY SECIRMARRD VSPFGNIPQR VMGQMGRSLL PSRTFLQALN LGIEVINTTD YLHFSKECSR ALLKMQYCPH CQGLALTKPC MGYCLNVMRG CLAHMAELNP HWHAYIRSLE ELSDAMHGTY DIGHVLLNFH LLVNDAVLQA HLNGQKLLEQ VNRICGRPVR TPTQSPRCSF DQSKEKHGMK TTTRNSEETL ANRRKEFINS LRLYRSFYGG LADQLCANEL AAADGLPCWN GEDIVKSYTQ RVVGNGIKAQ SGNPEVKVKG IDPVINQIID KLKHVVQLLQ GRSPKPDKWE LLQLGSGGGM VEQVSGDCDD EDGCGGSGSG EVKRTLKITD WMPDDMNFSD VKQIHQTDTG STLDTTGAGC AVATESMTFT LISVVMLLPG IW
Explore Glypican-5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets